| Study 1 | Study 2 | Total | |
| No. of patients (male/female) | 34(22/12) | 28 (13/15) | 62 (35/27) |
| Median age (range), years | 65 (35–89) | 67 (41–78) | 66 (35–89) |
| Family history of CRC | 4 (11.8%) | 6 (21.4%) | 10 (16.1%) |
| Right colon cancer | 9 (26.5%) | 13 (46.4%) | 22 (35.5%) |
| Left colon cancer | 25 (73.5%) | 15 (53.6%) | 40 (64.5%) |
| Preoperative radiotherapy* | 6 (17.6%) | 1 (2.9%) | 7 (11.3%) |
| Preoperative immunotherapy† | 18 (52.9%) | 8 (28.6%) | 26 (41.9%) |
| Histology | |||
| Moderately differentiated | 32 (94%) | 26 (93%) | 58 (93.5%) |
| Poorly differentiated | 2 (5.9%) | 2 (7.1%) | 4(6.5%) |
*Preoperative short course radiotherapy consisted of 25 Gy/5 fractions given over 1 week.
†Preoperative immunonutrition (Oral Impact (Novartis)) consisted of a mixture of omega-3 fatty acids, arginine, antioxidants and soluble fibre given for a week before the planned surgery.
CRC, colorectal cancer.